Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
  • Other Publications
    • Ochsner Journal Blog

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Ochsner Journal
  • Other Publications
    • Ochsner Journal Blog
  • My alerts
  • Log in
Ochsner Journal

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
Research ArticleUnder the Microscope

Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics

Om Prakash, Stephen F. Bardot and John T. Cole
Ochsner Journal June 2007, 7 (2) 61-64;
Om Prakash
Laboratory of Molecular Oncology, Ochsner Clinic Foundation, New Orleans, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen F. Bardot
Department of Urology, Ochsner Clinic Foundation, New Orleans, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Cole
Department of Hematology/Oncology, Ochsner Clinic Foundation, New Orleans, LA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading
  • Src
  • Lyn
  • CML
  • B-CLL

INTRODUCTION

Much of our current understanding of oncogenesis arose from a 1911 finding by American pathologist Peyton Rous that cell-free extracts of a chicken fibrosarcoma transmitted the disease to other chickens, indicating that the tumor was due to a “transmissible agent.” More than 40 years later, this led to the discovery of Rous sarcoma virus (RSV), named for its discoverer (1). In 1966, at the age of 87, Rous was awarded a Nobel Prize in recognition of his discovery of tumor-inducing viruses. The evidence that RSV is a retrovirus (RNA) tumor came from the Nobel Prize-winning discovery of reverse transcriptase by Howard Temin (2) and David Baltimore (3), which indicates that the viral genome is reverse transcribed into a DNA copy that becomes integrated into the host chromosome DNA as a provirus. This new genetic information acquired by the host serves as a source of virus production.

DISCOVERY OF CANCER GENES

The malignant changes induced by RSV are the consequence of the expression of a single viral oncogene, termed v-src for viral sarcoma, v-src is a 60 kDa nonreceptor tyrosine kinase that has the unusual specificity of phosphorylating tyrosine residues of critical cellular substrates, resulting in the activation of oncogenic transduction pathways. Expression of v-src in susceptible avian or mammalian cells leads to transformation in vitro and tumorigenesis in vivo (4,5). The discovery that RSV contained a defined gene for transformation opened a new frontier in the search for genes that might be involved in cancer. Eventually, the pioneering work of Mike Bishop and Harold Varmus led to the discovery of the normal cellular counterpart of the oncogene v-src, termed c-src, which in 1989 earned them the Nobel Prize in Physiology and Medicine. The term “protooncogene” was coined to describe the new types of genes, distinguishing them from the oncogenes.

STRUCTURE AND REGULATION OF SRC KINASES

The discovery that c-src is the normal cellular counterpart of the v-src led to the efforts to unveil the structural and functional differences between the two. Like its viral counterpart v-src, c-src also encodes a non-receptor tyrosine kinase. However, unlike v-src, the tyrosine kinase activity in c-src is tightly regulated and, for the most part, is maintained in an inactive state, activated transiently in response to specific stimuli. The main difference is found in the structure of their C-terminal regions, c-src has seven domains: an N-terminal membrane-association domain (SH4); a unique domain; SH3 and SH2 domains; an SH2-kinase linker domain; a tyrosine kinase domain (SH1); and a short c-terminal domain that plays a significant role in regulation of Src kinase activity (Fig. 1). The catalytic activity of Src family kinases is determined by the phosphorylation status of key tyrosine residues in their molecules. Positive regulation of human c-src protein occurs through autophosphorylation of tyrosine (Tyr) 419 (Tyr 416 in chickens), which is located in the SH1 domain and is required for optimal activity. Following autophosphorylation, the enzyme is stabilized in its active form. The negative regulation involves binding of phosphorylated Tyr 530 (Tyr 527 in chickens) in the human c-src protein to its own SH2 domains, which results in inactive conformation. Src with phosphorylated Tyr 530/527 cannot undergo Tyr 419/416 autophosphorylation. Under basal conditions in vivo, 90%–95% of Src is phosphorylated at Tyr 530/527. Dephosphorylation results in the unfolding of Src family kinases (SFKs), exposing Tyr 419/416, which requires phosphorylation for full activity. The loss of Tyr 530/527 or its dephosphorylation leads to stimulation of Src catalytic activity.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Domain structures of v-src and c-src proteins. Note the difference in their C-terminal regions. The first number is for human and the second for chicken c-src proteins.

Although the structure of v-src and c-src is similar, the two proteins differ, primarily in their regulatory C-terminal regions. V-src lacks the 19 amino acids present in the regulatory C-terminal region of c-src. The negative regulatory phosphorylation site is thus deleted, resulting in high levels of kinase activity and transforming ability (Fig. 1). The kinase activity of v-src and its transforming ability are much higher than c-src. The first genetic evidence that activating Src mutations may have a role in advanced human colon cancers came from the observation that in metastases of human colon cancer, c-src has mutations just in this region in a small subset of patients (6). However, such mutations were not detected in other studies (7), suggesting that genetic activation of c-src is a rare occurrence. Rather, Src protein kinase levels and Src kinase activity are frequently elevated in different cancers, including colorectal, breast, pancreatic, lung, neural, ovarian, and other common human cancers (8). Several possible mechanisms have been proposed, including direct or indirect interactions with receptor tyrosine kinases or defects in the phosphorylation of the carboxyl-terminal residue (Tyr 530/527), the primary phosphorylation site involved in the inactivation of c-src, suggesting that the process is multifactorial (8,9).

To date, a total of 11 distinct members of the Src family of kinases have been identified in humans (10). These include Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, Src, Srm, and Yes. They share extensive homologies in the catalytic domains but little homology in the amino-terminal regions, which may contribute to their unique biological functions (11). Among all family members, c-src is most frequently implicated in human cancers, including those of the colon, breast, pancreas, and brain. Lyn, one of the members of this family, is the predominant SFK involved in cell survival in heamatopoietic cell lineages (12). However, recent studies indicate that the Lyn kinase may be involved in the pathogenesis of certain solid and hematologic malignancies.

LYN KINASE: ROLE IN HEMATOLOCIC MALIGNANCIES

Lyn is over-expressed and activated in freshly isolated malignant B lymphocytes from the peripheral blood of B cell chronic lymphocytic leukemia (B-CLL) patients compared with normal B lymphocytes. Addition of the Lyn inhibitors to B-CLL cell cultures induced apoptosis, suggesting that Lyn contributed to the defective apoptosis of the leukemic cells (13). Lyn is also the most predominant SFK in primary leukemic cells from acute myeloid leukemia (AML) patients (14). Mutations found in Flt3, a hematopoietic growth factor receptor, in AML cause constitutive Lyn phosphorylation and activation. Targeting Lyn in mice transplanted with Flt3 mutation-expressing murine myeloid cells blocked the onset of tumors and decreased the size of established tumors (15).

Chronic myelogenous leukemia (CML) is characterized by the Philadelphia (Ph) translocation t(9;22)(q34;q11.2), which results in the formation of a bcr-abl fusion gene that translates an oncogenic protein-tyrosine kinase with transforming activity for hematopoietic cells. Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) is a potent and selective inhibitor of Bcr/abl tyrosine kinase and is the first choice treatment for all newly diagnosed CML patients. However, nearly 4% of the newly diagnosed patients on imatinib develop resistance to the drug. Studies have shown that Lyn expression is elevated in peripheral blood lymphocytes taken from patients with advanced CML that progressed on imatinib mesylate (Gleevec) therapy. Antisense oligonucleotides or short interfering RNA (siRNA) that suppressed Lyn expression had potent inhibitory effects on the growth of imatinib-resistant human CML cells (16,17). Lyn activation also plays a functional role in upregulation of Bcl-2, an antiapoptotic protein, in CML cells displaying Bcr/Abl-independent forms of imatinib resistance (18). These results clearly supported a role for Lyn kinase in the growth and apoptotic protection of imatinib-resistant CML cells. The novel observation that overexpression of Lyn is associated with imatinib resistance prompted investigation into the use of dual Bcr-Abl/SFK inhibitors. Several of these inhibitors from various chemical classes have been found to be 100 to 300 times more effective than imatinib (19).

LYN KINASE: ROLE IN SOLID TUMORS

Lyn overexpression and activation in colon carcinoma cells confers chemoresistance (20). Lyn kinase activity is significantly elevated in glioblastoma tumor biopsies compared with non-neoplastic brain biopsies. In the tumors, Lyn kinase activity accounts for >90% of the total Src kinase activity, compared with only ∼30% in non-neoplastic brain tissues. These results suggested that Lyn kinase promoted malignant transformation of glioblastoma tumors (21).

Lyn is expressed in a majority of primary human prostate cancers (22). Inhibition of Lyn activity using a sequence-based Lyn inhibitor peptide decreases proliferation of hormone refractory prostate cancer cell lines and significantly reduces tumor growth in a tumor explant model. Thus, Lyn may serve as a prime target for the treatment of malignancies that are linked to deregulated Lyn expression/activation.

CONCLUSION

The pioneering work on the Rous sarcoma virus was directly responsible for the discovery of cellular protooncogenes, which has been fundamental in shaping our understanding of cellular growth control. Over the last 50 years, advances in the understanding of cancer biology have made it increasingly clear that the activation of oncogenes often results in the deregulation of complex cell-signaling pathways that promote proliferation, apoptotic-resistance, angiogenesis, and metastasis. Hence, the signaling components of these deregulated pathways provide selective targets to guide therapeutic decisions.

Lyn kinase, once considered an exclusive B-cell signaling molecule involved in the pathogenesis of hematologic malignancies, has more recently been shown to play a role in solid tumors. Thus, one can envision targeting a wide range of malignancies with the same inhibitor as a single agent or in combination with other therapies.

Imatinib mesylate is the first successful example of a tyrosine kinase inhibitor for CML. However, the initial striking success of this drug has been clouded by the development of clinical resistance that mostly coincides with the activation of SFKs. This prompted the development of dual Src and Abl inhibitors such as dasatinib (Bristol-Myers Squibb, New York, NY), which targets Bcr-Abl and multiple SFKs, and INNO-406 (Innovive Pharmaceuticals, New York, NY), which targets Bcr-Abl and a single SFK Lyn kinase. In preclinical studies, these inhibitors and others were several times more effective than imatinib. Although originally designed for CML, dasatinib also shows activity against epithelial tumor cells, including human prostate and breast cancer cells (23). Dasatinib has recently been approved by the US Food and Drug Administration for the treatment of imatinib-resistant and imatinib-tolerant CML, as well as the treatment of therapy-resistant Ph+ acute lymphoblastic leukemia (24). Thus, the dual Bcl-Abl/SFK inhibitors represent a major success in targeted chemotherapy and also have potential as therapeutic agents for cancers harboring activated SFKs.

The more we learn about the deregulated cell signaling pathways induced by the activation of oncogenes, the better we are able to design new strategies to improve cancer treatment. This is especially critical for the subpopulation of patients who fail to respond to conventional chemotherapies. We continue to learn from clinical experience that patients may respond much better to pathway-driven therapeutics than to standard cytotoxic chemotherapies. Thus, deciphering the critical pathways that the oncogenes or inactivation of tumor suppressor genes regulate will translate into greater benefits for cancer patients by a more precise matching of therapy with disease mechanism(s).

  • Ochsner Clinic and Alton Ochsner Medical Foundation

References

  1. ↵
    1. Rubin H.
    (1955) Quantitative relations between causative virus and cell in the Rous no. 1 chicken sarcoma. Virology 1:445–473, pmid:13274745.
    OpenUrlPubMed
  2. ↵
    1. Temin H. M.,
    2. Mizutani S.
    (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226:1211–1213, pmid:4316301.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Baltimore D.
    (1970) RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226:1209–1211, pmid:4316300.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Morgan J. C.,
    2. Majors J. E.,
    3. Galileo D. S.
    (2005) Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation. Clin Exp Metastasis 22:167–175, pmid:16086237.
    OpenUrlPubMed
  5. ↵
    1. Stoker A. W.,
    2. Sieweke M. H.
    (1989) v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus. Proc Nat Acad Sci U S A 86:10123–10127.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Irby R. B.,
    2. Mao W.,
    3. Coppola D.
    (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190, pmid:9988270, et al.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ishizawar R.,
    2. Parsons S. J.
    (2004) c-src and cooperating partners in human cancer. Cancer Cell 6:209–214, pmid:15380511.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Irby R. B.,
    2. Yeatman T. J.
    (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636–5642, pmid:11114744.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Chen T.,
    2. George J. A.,
    3. Taylor C. C.
    (2006) Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 17:123–131, pmid:16428929.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Roskoski R. Jr..
    (2004) Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324:1155–1164, pmid:15504335.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Yi T. L.,
    2. Bolen J. B.,
    3. Ihle J. N.
    (991) Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Mol Cell Biol 11:2391–2398, pmid:2017160.
    OpenUrlPubMed
  12. ↵
    1. Prakash O.,
    2. Swamy O. R.,
    3. Peng X.
    (2005) Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 105:3987–3994, pmid:15665117, et al.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Contri A.,
    2. Brunati A. M.,
    3. Trentin L.
    (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115:369–378, pmid:15650771, et al.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Robinson L. J.,
    2. Xue J.,
    3. Corey S. J.
    (2005) Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 33:469–479, pmid:15781338.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Okamoto M.,
    2. Hayakawa F.,
    3. Miyata Y.
    (2007) Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 21:403–410, pmid:17230226, et al.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Donato N. J.,
    2. Wu J. Y.,
    3. Stapley J.
    (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690–698, pmid:12509383, et al.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Ptasznik A.,
    2. Nakata Y.,
    3. Kalota A.
    (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1 (+) leukemia cells. Nat Med 10:1187–1189, pmid:15502840, et al.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Dai Y.,
    2. Rahmani M.,
    3. Corey S. J.
    (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227–34239, pmid:15175350, et al.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Kimura S.,
    2. Naito H.,
    3. Segawa H.
    (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948–3954, pmid:16105974, et al.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Bates R. C.,
    2. Edwards N. S.,
    3. Burns G. F.,
    4. Gisher D. E.
    (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3- kinase/Akt in colon carcinoma cells. Cancer Res 61:5275–5283, pmid:11431370.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Stettner M. R.,
    2. Wang W.,
    3. Nabors L. B.
    (2005) Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 65:5535–5543, pmid:15994925, et al.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Goldenberg-Furmanov M.,
    2. Stein I.,
    3. Pikarsky E.
    (2004) Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 64:1058–1066, pmid:14871838, et al.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Nam S.,
    2. Kim D.,
    3. Cheng J. Q.
    (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostrate cancer cells. Cancer Res 65:9185–9189, pmid:16230377, et al.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Shah N. P.
    (2007) Dasatinib. Drugs Today (Bare) 43:5–12.
    OpenUrl
PreviousNext
Back to top

In this issue

Ochsner Journal
Vol. 7, Issue 2
Jun 2007
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Ochsner Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics
(Your Name) has sent you a message from Ochsner Journal
(Your Name) thought you would like to see the Ochsner Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics
Om Prakash, Stephen F. Bardot, John T. Cole
Ochsner Journal Jun 2007, 7 (2) 61-64;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics
Om Prakash, Stephen F. Bardot, John T. Cole
Ochsner Journal Jun 2007, 7 (2) 61-64;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • INTRODUCTION
    • DISCOVERY OF CANCER GENES
    • STRUCTURE AND REGULATION OF SRC KINASES
    • LYN KINASE: ROLE IN HEMATOLOCIC MALIGNANCIES
    • LYN KINASE: ROLE IN SOLID TUMORS
    • CONCLUSION
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Isolation of Endothelial Cells and Vascular Smooth Muscle Cells from Internal Mammary Artery Tissue
  • Inhibition of Erythroleukemia Cell Growth by Triplex-forming RNAs
Show more Under the Microscope

Similar Articles

Keywords

  • Src
  • Lyn
  • CML
  • B-CLL

Current Post at the Blog

No Author Credit for ChatGPT

Our Content

  • Home
  • Current Issue
  • Ahead of Print
  • Archive
  • Featured Contributors
  • Ochsner Journal Blog
  • Archive at PubMed Central

Information & Forms

  • Instructions for Authors
  • Instructions for Reviewers
  • Submission Checklist
  • FAQ
  • License for Publishing-Author Attestation
  • Patient Consent Form
  • Submit a Manuscript

Services & Contacts

  • Permissions
  • Sign up for our electronic table of contents
  • Feedback Form
  • Contact Us

About Us

  • Editorial Board
  • About the Ochsner Journal
  • Ochsner Health
  • University of Queensland-Ochsner Clinical School
  • Alliance of Independent Academic Medical Centers

© 2023 Ochsner Clinic Foundation

Powered by HighWire